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Conversion of the soluble, nontoxic amyloid β-protein (Aβ) into an aggregated, toxic form rich in β-sheets is a key step in the
onset of Alzheimer’s disease (AD). It has been suggested that Aβ induces changes in neuronal membrane ﬂuidity as a result of its
interactions with membrane components such as cholesterol, phospholipids, and gangliosides. Gangliosides are known to bind
Aβ.Ac o m p l e xo fG M 1a n dA β,t e r m e d“ G A β”, has been identiﬁed in AD brains. Abnormal ganglioside metabolism also may
occur in AD brains. We have reported an increase of Chol-1α antigens, GQ1bα and GT1aα, in the brain of transgenic mouse AD
model. GQ1bα and GT1aα exhibit high aﬃnities to Aβs. The presence of Chol-1α gangliosides represents evidence for genesis
of cholinergic neurons in AD brains. We evaluated the eﬀects of GM1 and Aβ1–40 on mouse neuroepithelial cells. Treatment of
these cells simultaneouslywith GM1 and Aβ1–40 caused a signiﬁcant reduction of cell number, suggesting that Aβ1–40 and GM1
cooperatively exert a cytotoxic eﬀect on neuroepithelial cells. An understanding of the mechanism on the interaction of GM1 and
Aβs in AD may contribute to the development of new neuroregenerative therapies for this disorder.
1.Introduction
Alzheimer’sdisease(AD)isanirreversible,slowlyprogressive
neurodegenerative disease that is the most common form of
dementiaamongpeopleage65andolderandischaracterized
by cognitive and behavioral problems. The symptoms are
initiated by memory loss and gradually lead to behavior and
personality changes with impaired cognitive abilities such
as decline of decision making and language disability, and
eventually disturbances in recognizing family and friends.
These losses are related to the worsening lesion of the
connections between certain neurons in the brain. Patients
often become anxious or aggressive, or wander away from
home. Eventually, patients need total care, and the ﬁnal
outcomeisalwaysdeath.Althoughthereisnocureatpresent,
some therapeutic drugs inhibiting acetylcholinesterase have
been used to alleviate the disease symptoms and improve the
quality of life for patients with AD [1, 2].
Gangliosides are important constituents of cells; they
are especially abundant in neuronal membranes and play a
variety ofbiological functions, including cellular recognition
and adhesion as well as signaling [3]. The expression of
gangliosides is not only cell type speciﬁc and developmen-
tally regulated but also closely related to the diﬀerentiation
state of the cell [3–6]. Numerous studies have indicated
that changes of ganglioside expression patterns and levels
during cellular diﬀerentiation are closely related to their
metabolism, particularly their biosynthesis [3, 4, 6]. Notably,
gangliosides may have neuroprotective eﬀects to the cell [7].
Gangliosides do not function as a neurotrophic factor them-
selves, but they potentiate neurotrophic inﬂuences present
in the nervous system. In this regard, many scientists have
reported the beneﬁcial eﬀects of GM1 treatment in animal
models of neurodegeneration and diseases. For example,
administration of GM1 protects hippocampal progenitor
cells from neuronal injury and reduces hippocampal neu-
rogenesis induced by D-galactose treatment [8]. Saito et al.
reported that GM1 and LIGA20 can protect mouse brains
from apoptotic neurodegeneration induced by ethanol [9].
In clinical applications or animal studies, many studies have2 International Journal of Alzheimer’s Disease
demonstrated the neuroprotective eﬀects of GM1 in diseases
such as AD [10], AD model of transgenic mice [11, 12],
Parkinson disease [13], stroke [14], and Guillain-Barr´ es y n -
drome [15].
The pathological hallmarks in the AD brain include
senile plaques (SPs) and neuroﬁbrillary tangles. Many sci-
entists believe that the accumulation and aggregation of
amyloid β-proteins (Aβs )i nS P si nt h eb r a i na r eac e n t r a l
part of the pathogenesis of AD. The conversion of soluble,
nontoxic Aβ into aggregated, toxic Aβ rich in β-sheet struc-
tures is considered to be the key step in the development
of AD. Aβs are able to bind to a variety of biomolecules,
including lipids, proteoglycans, and certain proteins [1, 16].
Immunochemical studies revealed that Aβ deposits in AD
brain are due to the presence of certain amyloid-associated
proteins such as amyloid P component, proteoglycans,
and apolipoproteins [17]. The potential signiﬁcance of the
interaction with proteoglycans and Aβsf o rt h ep a t h o g e n i c
mechanisms has been reviewed [2].
During aging and neurodegeneration in AD, the physic-
ochemical properties of membranes and lipid metabolism
undergo signiﬁcant alterations [18, 19]. These include mul-
tiple changes such as glycosphingolipid (GSL) abnormalities
and impairment of neurotrophin signaling, protein traﬃck-
ing, and protein turnover [20]. These changes can result in
imbalances in the proportion of lipids in membranes and/or
changed ratios of membrane lipids, which may contribute
to the pathogenesis of AD [21–23]. Earlier immunohisto-
chemical studies on the involvement of GSLs using speciﬁc
monoclonal antibodies revealed that SPs contained GM1
[24], c-series gangliosides [25], and GD1a [26], and these
studies implicate that Aβs might be interacting with the
above gangliosides. In this paper, we will focus on the
role of ganglioside metabolism in the pathogenesis and/or
development of AD.
2.InteractionofAmyloid β-Proteinswith
Gangliosides
A critical question concerning the development of AD is
how the soluble, nontoxic Aβ form high in an α-helix-rich
structure is converted into an aggregated, toxic form rich in
β-sheets in the brain. Terzi et al. ﬁrst reported that Aβ1–40
undergoes a conformational transition from random coil to
aggregated structure rich in β-sheet after addition of lipid
vesicles containing negatively charged lipids [27], suggesting
that Aβ neurotoxicity may be the result of membrane
protein-lipid interactions. Severalstudieshavedemonstrated
that Aβs bind to gangliosides, especially GM1, resulting in
an altered secondary structure of Aβs[ 28–31]. Aβ binds to
membranes containing ganglioside GM1, and upon binding
it undergoes a conformational transition from random coil
to an ordered structure rich in β-sheet. This interaction
appears to be ganglioside-speciﬁc because no changes in
Aβ1–40 conformation were found in the presence of various
phospholipids or sphingomyelin. Aβ binds selectively to
gangliosides with a binding aﬃnity ranging from 10−6 to
10−7 M, depending on the type of the sugar moiety present
in the ganglioside molecule. On the other hand, the isolated
oligosaccharide moieties of gangliosides are ineﬀective in
inducing alterations in the secondary structure of Aβ1–40
[28, 32], suggesting the involvement of the lipid component
in their interaction. The sialic acid (NeuAc) moiety of
gangliosides interacts with Aβ to induce conformational
changes in Aβ [31]. In this regard, we have reported that
Aβ1–40bindsto anumber ofgangliosides with the following
orderofbindingstrength: GQ1bα>GT1aα>GQ1b>GT1b
> GD3 > GD1a = GD1b > LM1 > GM1 > GM2 = GM3
> GM4 based on surface plasmon resonance studies [33].
Neutral GSLs, including asialo-GM1, generally have a much
lower aﬃnity for Aβ1–40 than do gangliosides. The results
suggest that the α2,3NeuAc residue on the oligosaccharide
core of gangliosides is required for binding. In addition,
the α2,6NeuAc residue linked to GalNAc in the α-series of
gangliosides contributes signiﬁcantly to the binding aﬃnity
for Aβ. Although several reports documented the GM1-
induced alterations in the β-sheet structure of Aβ,M a n d e l
and Pettegrew, on the other hand, reported that GM1 inhib-
ited Aβ from undergoing α-helix to β-sheet conformational
changes [34]. This discrepancy clearly needs further clariﬁ-
cation. In addition, asialo-GM1 binds speciﬁcally with Aβ in
a manner that could preventβ-sheet formation. Nakazawa et
al. reported that Aβ1–40 strongly perturbed the lipid bilayer
structure of liposomes of dimyristoylphosphatidylcholine
and GM1 to form a nonlamellar phase (most likely in the
micellar phase) [35]. The α-helical peptide conformation is
signiﬁcantly ﬂexibleandis approximatelyequallypartitioned
between components penetrated into the bilayer and in
liquid phase whereas the β-sheet peptide conformation is
rigid and is presumably deposited and stacked at the bilayer
surface.
The interaction between gangliosides and Aβ appears
to be aﬀected by experimental conditions such as pH,
ionic strength [30, 31], and metal ions [36, 37]. For
example, McLaurin and Chakrabartty have reported that
Aβ1–40/Aβ1–42 disrupts acidic lipid membranes, and this
disruption is greater at pH 6.0 than at pH 7.0, at which
point gangliosides induce Aβ1–40/Aβ1–42 to adopt a novel
α/β conformation [30]. A further study indicated that
bindingofAβ1–40tomixedgangliosides orGM1-containing
vesicles induced an α-helical structure at pH 7.0 and β-
structure at pH 6.0 [31]. Several lines of evidence have
indicated that disruption of the homeostatic balance of
redox-active biometals such as Cu and Fe can lead to
oxidative stress, which plays a key role in the development
of AD. Atwood et al. reported that unlike other biometals
tested at maximal biological concentrations, Cu2+-induced
aggregation of Aβ1–40 occurred as the solution pH was
lowered from 7.4 to 6.8 and that the reaction was completely
reversible with either chelation or alkalinization [36]. The
aggregation-inducing activity of metals is in the following
order, Cu2+ > Fe3+ > or = Al3+ > Zn2+ [37].
3.Binding Sitesof Amyloidβ-Proteins with
Gangliosides
The NeuAc residue of the ganglioside head group is impor-
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of Aβ [31, 38] or interaction with Aβ [33]. The isolated
pentasaccharide head group of GM1 alone, however, does
not bind with Aβ, suggesting the need for a polyanionic
membrane-like structure [38]. To provide a structural
basis for this pathogenic interaction associated with AD,
Williamson et al. have demonstrated using NMR on 15N-
labelled Aβ1–40 and Aβ1–42 that the interaction with GM1
micelles is localized to the N-terminal region of the peptide,
particularly residues His13 to Leu17, which become more
helical when GM1 is bound [38]. The key interaction is
withHis13,whichundergoesaGM1-speciﬁcconformational
change. Zhang et al. reported that the binding site for GM1
was located within residues 52–81 (N terminus) of amyloid
precursor protein (APP), resulting in a conformational
change of APP [39]. This phenomenon is speciﬁc for GM1,
but not for GD1a, GT1b, and ceramide, indicating that
speciﬁc binding depends on the sugar moiety of GM1.
Utsumi et al. reported the association of Aβ1–40 iso-
topically labeled with GM1 and lyso-GM1 micelles using
920MHz ultra-high ﬁeld NMR analyses [40]. The data re-
vealed that: (a) Aβ1–40, upon binding to the gangliosidic
micelles, forms discontinuous α-helices at the segments
His(14)-Val(24) and Ile(31)-Val(36), and (b) Aβ1–40 lies on
hydrophobic/hydrophilic interface of the ganglioside cluster,
exhibiting an up-and-down topological mode in which the
two α-helices and the C-terminal dipeptide segment are in
contactwith thehydrophobicinterior whereas theremaining
regions are exposed to the aqueous environment. These
results suggest that the ganglioside clusters serve as a unique
platformforbindingcoupledwithconformationaltransition
of Aβ molecules, rendering their spatial rearrangements
restricted to promote speciﬁc intermolecular interactions.
[40]. Further study of NMR analyses of the Aβ interactions
with gangliosides using lyso-GM1 micelles asa model system
have revealed that the sugar-lipid interface is primarily
perturbed upon binding of Aβ to the micelles, underscoring
the importance of the inner part of the ganglioside cluster
for accommodating Aβ in comparison with the outer
carbohydrate branches that provide microbial toxin- and
virus-binding sites [41].
4.AccumulationofSpeciﬁc
Ganglioside-BoundAmyloid β-Protein
Complex(GAβ)inADB rain
Choo-Smithetal.havereportedthatadditionofganglioside-
containing vesicles to the Aβ solution dramatically acceler-
ates the rate of ﬁbril formation compared to vesicles without
gangliosides [28]. The mechanism of ganglioside-mediated
Aβ-ﬁbrillization likely involves an initial step in which
t h eG S L - b o u n dp e p t i d es e l f - a s s o c i a t e so nt h em e m b r a n e
surface, undergoing a conformational transition to a β-sheet
structure. This suggests that gangliosides can mediate Aβ
assembly to lead to accumulation in the brain, which may
be involved in the development of AD. Yanagisawa et al.
ﬁrst reported the presence ofmembrane-bound Aβ1–42, but
not Aβ1–40, which tightly binds to GM1 in the AD brain
[42]. This novel Aβ species, named as ganglioside-bound
Aβ (GAβ), may act as an endogenous seed for amyloid
[42], and exhibited early pathological changes of AD. It
was hypothesized that Aβ adopts an altered conformation
following interaction with GM1, leading to the generation of
GAβ,a n dt h e nG A β acts as an endogenous seed for amyloid
in AD brain. GAβ has unique characteristics, including an
extremely high aggregation potential and an altered pattern
of immunoreactivity, which results in seeding for amyloid
ﬁbril formation in brain. Thus, GAβ may serve as a seed
for toxic amyloid ﬁbril formation. The formation of GAβ
serves as one of the critical factors in the development of AD
and may provide new insights into the pathophysiology in
AD [43] .T h eo c c u r r e n c eo fG A β in AD brain was further
conﬁrmed biochemically by staining with cholera toxin-
B subunit (CTXB) that preferentially binds to GM1, and
by immunoprecipitation experiments using several anti-Aβ
monoclonal antibodies [44]. Recently, the presence of GAβ
was conﬁrmed in sections of cerebral cortices of cynomolgus
monkeys of diﬀerent ages, from 4 to 36 years old; especially,
GAβ is signiﬁcantly increased in the brains at ages below 19
years [45]. In this study, the accumulation of GAβ occurred
exclusively in the subcellular organelles that are involved
in the endocytic pathway. Since Aβ generation and GM1
accumulation likely occur in early endosomes, it suggests
that endosomes are intimately involved in the Aβ-associated
pathology of AD [45]. In addition, Aβ aggregation in brain
is accelerated through an increase in the level of GM1 in
neuronal membranes [46, 47]. The eﬀect occurs in a dose-
dependent manner; in the presence of lower concentrations
of GM1 (approximately 25μM), Aβ1–40 forms aggregates
much more slowly, indicating that an increase in the
concentrationofGM1signiﬁcantlyfacilitatestheaggregation
of Aβ. Further studies have indicated that both GM1 and
GT1b promote the aggregation and cytotoxicity of Aβ1–
40, and these gangliosides, especially GM1, catalyze the
formationofneurotoxicﬁbrils[48].Moreover,bindingofAβ
to GM1 was dependent on cholesterol-induced clustering of
GM1 in the host membranes. An increase in the cholesterol
concentration in the neuronal membranes accelerates Aβ
aggregation through the formation of an endogenous seed
[49, 50], consistent with the notion that cholesterol is also
a risk factor for AD development. These results further
underscore the importance of control of cellular cholesterol
and/or ganglioside contents in the pathogenesis of AD [50–
52]. Lin et al. reported the role of GM1 and cholesterol on
the Aβ-induced cytotoxicity in the plasma membrane [53].
Depletion of GM1 from the plasma membrane would be
expected to block the Aβ-induced cytotoxicity. Decreasing
the cholesterol level by around 30% could also attenuate the
cytotoxicity of Aβ. These ﬁndings validate that cholesterol
can stabilize the lateral pressure derived from formation of
the GM1-Aβ complex on the membrane surface and that
both GM1 and cholesterol are essential for Aβ accumulation.
Zha et al. reported that GM1 regulated the expression of Aβ
in a dose-dependent manner [54]. Exogenously added GM1
increased Aβ levels in mixed rat cortical neurons containing
African green monkey epithelial kidney cells (COS7) and
human neuroblastomacells (SH-SY5Y)that weretransfected
with APP695 cDNA.4 International Journal of Alzheimer’s Disease
Yanagisawa and coinvestigatorsdevelopeda novel mono-
clonal antibody, 4396C, raised against GAβ puriﬁed from an
AD brain [55]. Using this antibody, the presence of GAβ was
conﬁrmed in the AD brain, in which GAβ is endogenously
generated. The antibody reacted with GM1-bound forms of
two Aβ isoforms, Aβ1–40 and Aβ1–42, but not the unbound
forms of Aβ1–40 and GM1. Remarkably, using liposomes
containing Aβ1–40 and GM1, this antibody completely
blocksamyloid ﬁbrilformationinadose-dependentmanner,
suggesting that it may act to inhibit the initiation of
oligomerization-polymerization of Aβ in the brain and serve
in the possible development of a novel therapeutic strategy
to the GAβ-dependent amyloidogenesis [55, 56]. The age-
dependent high-density GM1 clustering at the presynaptic
neuritic terminals is a critical step for Aβ deposition in AD.
In amyloid-positive synaptosomes prepared from AD brain,
GM1 levels are signiﬁcantly increased when Aβ deposition
begins at presynaptic terminals. The antibody against GAβ,
4396C, suppressed Aβ assembly in the synaptosomes [57].
Moreover, peripheral administration of the Fab fragments
of 4396C into transgenic mice expressing a mutant amyloid
precursor protein gene, following the conjugation of the
protein transduction domain of the Tat protein, markedly
suppressed Aβ deposition in the brain [58].
Interestingly, the enhanced GAβ-dependent amyloido-
genesis under the endocytic dysfunction was suppressed by
pretreatment with a sphingomyelinase synthase inhibitor,
suggesting that sphingomyelin is also one of the key
molecules for GAβ generation, further implying that the
interaction of Aβ with membrane lipids is critical in amyloid
ﬁbrillization in the brain [59]. In addition, the expression
of apolipoprotein E4 may facilitate Aβ assembly in the
brain through an increase in the GM1 content in neuronal
membranes, which likely induces GAβ generation [43, 47,
60].
In recent years, evidence has been presented that “lipid
rafts” are the preferential sites for the formation of the
pathological forms of Aβ [61]. GAβ is generated in the
membraneraft-likemicrodomains,comprisedofcholesterol,
sphingomyelin, and GM1 [62, 63], in which Aβ undergoes a
conformational transition from an α-helix-rich structure to
a β-sheet-rich structure or oligomerization with the increase
in protein density on the membrane. GM1 induced amyloid
ﬁbrillization, especially under β-sheet-forming conditions,
leading to the generation and seeding of GAβ.T h u s ,
ganglioside binding with Aβ is the initial and common step
in thedevelopmentofa part ofhuman misfolding-type amy-
loidoses, including AD [64]. The level of GAβ is increased,
and its α-helix structure is converted into a β-sheet structure
[65]. Thus, the formation of amyloid ﬁbrils or oligomers
is likely mediated by gangliosides in lipid rafts [66], and
depletion of gangliosides or cholesterol signiﬁcantly reduces
the amount of amyloid deposits [48, 67].
5.Other GangliosidesMayBe Involved In
the GenerationofGAβ
Other gangliosides have been shown to interact with Aβ,
which may lead to Aβ accumulation in the brain. The
assembly of wild-type and mutant forms of Arctic-, Dutch-,
and Flemish-type of Aβs is accelerated in the presence
of not only GM1, but also GM3 and GD3 gangliosides.
Dutch and Italian-type Aβs require GM3 ganglioside for
their assembly [47]. Arctic-type Aβ, in contrast to the wild-
type and other variant forms, shows a markedly rapid and
higher level of amyloid ﬁbril formation in the presence
of sodium dodecyl sulfate or GM1 ganglioside [68]. These
results provide evidence that local gangliosides play a crucial
role in the region-speciﬁc Aβ deposition in the brain [69,
70]. Gangliosides are located mostly on the cell surface and
havebeendemonstratedtomodulateneurotrophicactivities.
The localization of GD1a in dystrophic neurites suggests
that such neurites accumulate GD1a as a membranous
component. In addition, the accumulation of GD1a in SPs
suggests that it may contribute to SP formation [26]. In a
study for the interaction of Aβs with GM1 using rat adrenal
medulla pheochromocytoma cells (PC12 cells), Wakabayashi
et al. used CTXB for detection of GM1 [71]. However, the
ganglioside that interacted with Aβs in PC12 cells may not
be deﬁnitely GM1 because CTXB also strongly reacted also
with fucosyl-GM1 and fucosyl-GD1b [72]a n dP C 1 2c e l l s
express fucosyl gangliosides including fucosyl-GM1 [73, 74]
with littleorno GM1 [75].WhenPC12 cellswere culturedin
the presence of Aβ1–40 or Aβ1–42, Aβs accumulated in cells
expressing fucosyl gangliosides [72]. Thus, the interaction
of Aβ with gangliosides to eﬀect amyloid assembly may
not be limited to GM1; indeed, other gangliosides should
also be involved in “seeding” [1, 72]. Molander-Melin et
al. reported that the detergent-resistant membrane fractions
from thefrontal cortexofADbrains containedasigniﬁcantly
higher concentration of ganglioside GM1 and GM2 [76].
The increased proportions of GM1 and GM2 in lipid rafts
at an early AD stage could accelerate the formation of Aβ
plaques, which gradually causes membrane raft disruptions
and thereby aﬀects cellular functions that are dependent on
t h ep r e s e n c eo fs u c hm e m b r a n ed o m a i n s .
6.GangliosideMetabolisminADBrainsandAD
Model Mouse Brains
Aβ changes in membrane ﬂuidity could be induced by
chemical interactions of the peptide with membrane com-
ponents such as cholesterol, phospholipids, and gangliosides
[77]. Since gangliosides have a strong aﬃnity to Aβs[ 33],
they could participate in conformational changes of Aβsi n
membrane ﬂuidity. For this reason, ganglioside metabolism
has been considered to be closely associated with the
pathogenesis of AD [1, 20]. Several earlier studies showed
signiﬁcant changes of ganglioside patterns in AD brain. The
concentration of gangliosides decreased in the majority of
brain regions, such as the cerebral cortex, hippocampus,
and basal telencephalon, especially in the frontal cortex
and white matter [78–80]. Kracun et al. reported that the
major brain ganglio-N-tetraosyl-series ganglioside species
(GT1b, GD1b, GD1a, and GM1) signiﬁcantly decreased in
the frontal and temporal cortices and basal telencephalon
of the brains of patients with AD compared with the
respective areas in control brain [81, 82]. Brooksbank andInternational Journal of Alzheimer’s Disease 5
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McGovern [83]a n dC r i n oe ta l .[ 84] also reported changes
of ganglioside composition in AD brains in which b-series
gangliosides, such as GT1b and GD1b, showed a signiﬁcant
decrease, in contrast to a slight increase in GT1a, GD3,GM1,
and GM2. These ﬁndings suggest that abnormal ganglioside
metabolism coincides with the aﬀected cortical areas of
neurodegeneration that aﬄicts AD.
In contrast to these human studies, we found no signif-
icant diﬀerences in the lipid-bound NeuAc content in the
brain slices containing hippocampal/cortical tissue prepared
from AD model double transgenic (Tg) mice coexpressing
mouse/human chimeric APP with the Swedish mutation
and human presenilin-1 with a deletion of exon 9 and age-
matched wild-type (WT) mice, even though Aβsw e r ef o u n d
to be accumulated in the brain (Figure 1) and serum of these
Tg AD model mice [85] .I na d d i t i o n ,t h e r ew a sn os i gn i ﬁ c a n t
diﬀerence in the expression levels of major gangliosides
( G M 1 ,G D 1 a ,G D 1 b ,a n dG T 1 b )i nt h eb r a i n sb e t w e e n
doubleTg andage-matched WT mice.This isconsistentwith
t h er e p o r tb yS a w a m u r ae ta l .[ 86] who also did not detect
notable changes in the major gangliosides in the brain of
mutantpresenilin-2 Tgmice,despitetheremarkableincrease
in the levelofAβ1–42 and statistically signiﬁcant lower levels
of glycerophospholipids and sphingomyelin. In addition,
Bernardo et al. also did not ﬁnd signiﬁcant diﬀerences in
a- or b-series gangliosides between WT and double Tg mice
expressing APP with the Swedish mutation and presenilin-
1 with a deletion of exon 9 [87]. These studies as well as
our recent data indicate no signiﬁcant changes in the major
brain ganglioside metabolism in AD model mice, despite
the presence of massive accumulation of Aβ deposits in the
brains of these animals. Barrier et al. reported an increase
of GM2 and GM3 within the cortices of Tg mice expressing
human APP751 with Swedish and London mutations and
human presenilin-1 (M1461) [88].
The most consistent and interesting ﬁnding of our recent
study is the increased expression of cholinergic-speciﬁc
antigen-1α (Chol-1α)a n t i g e n s ,G T 1 a α, and GQ1bα (see
Scheme 1), especially GQ1bα,i nt h eb r a i no fd o u b l eT gm i c e
as compared with those in WT mouse brains (Figure 2).
The increase was especially signiﬁcant in female double Tg
mouse brains. No signiﬁcant diﬀerences were found in the
expression of GT1aα and GQ1bα between male and female
W Tm o u s eb r a i n s .T h e s eg a n g l i o s i d e sa r en o r m a l l ym i n o r
species in the brain and serve as markers of cholinergic
neurons [89, 90]. The expression of Chol-1α antigens in rat
brain regions such as the hippocampus is developmentally
regulated, and their concentrations increase with aging [91].
Although the functional role of Chol-1α antigens in Tg
mice brain has remained obscure, Ando et al. reported
that the release of acetylcholine from synaptosomes was
inhibited by anti-Chol-1α monoclonal antibody [92]. The
memory and learning abilities of rats given anti-Chol-1α
antibody were remarkably suppressed. On the contrary,
the treatment of Chol-1α antigen induced choline uptake
by synaptosomes. As a result of increased choline uptake,
acetylcholine synthesis was enhanced by Chol-1α antigens.
Chol-1α antigens are speciﬁcally expressed in the cholinergic
neutrophilandmayparticipateincognitivefunctionssuchas
memory and learning. Beneﬁcial eﬀects of Chol-1α antigens
were shown to ameliorate decreased functions of synapses
from aged brains, suggesting that Chol-1α antigens may
play a pivotal role in cholinergic synaptic transmission
and participates in cognitive function [93]. Interestingly,
Chapman et al. reported the presence of serum antibody in
patientswithADthatspeciﬁcallybindtocholinergicneurons
[94]. The increasing antibody in the patient’s sera may
be attributed to the increase of Chol-1α antigens in AD
brain. Cholinergic neuronal dysfunction of basal forebrain
is observed in patients with AD, and has been linked
to decreased neurogenesis in the hippocampus, a region
involved in learning and memory [95]. They recently found
an increasing number of newborn cells in the dentate gyrus
of hippocampus in cholinergic-denervated mice compared
to nonlesioned mice, suggesting neurogenesis can occur
in Tg mice brain to generate new cells expressing Chol-
1α antigens. It would be extremely interesting to enhance
neurogenesis in hippocampus of patientsand animal models
of AD [96–99].
In addition to the above, AD model animals with dis-
rupted ganglioside biosynthesis have been reported to reveal
relationships between ganglioside metabolism and aspects of
AD. For example, Oikawa et al. crossbred Tg mice expressing
human APP having Swedish and London mutations with
GM2-synthase knockout mice [100]. The mutant mice
expressing GM3 and GD3, but not GM1, GD1a, GD1b, and
GT1b, showed a signiﬁcant increase of Aβ accumulation
in vascular tissues and formation of severe dysphonic-form
amyloid angiopathy in the brain. In contrast, Bernardo et
al. analyzed the AD model of Tg mice expressing APP with
the Swedish mutation and presenilin-1 with a deletion of
exon 9 that crossbred with mice deﬁcient in GD3-synthase,
which catalyzes the synthesis of b-series gangliosides [87].
In the triple mutant mice, b-series gangliosides, including
GD3, were completely absent, but GM1 and GD1a were
signiﬁcantly increased. Interestingly, Aβ plaques and associ-
ated neuropathology were almost completely eliminated in
the triple mutant mice, resulting in cognitive improvement
[87]. These observations suggest that b-series gangliosides
synthesized by GD3-synthase are one of the major causes of
Aβ accumulation and AD. Thus, inhibition of GD3-synthase
can be a novel therapeutic target to combat the cognitive
deﬁcits, amyloid plaque formation, and neurodegeneration
seen in AD.
In this regard, Okada et al. reported that endoge-
nously generated b-series gangliosides may be critical for6 International Journal of Alzheimer’s Disease
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Figure 1: Immunohistochemicallocalizationof Aβs in the cortex ofdouble transgenic mice coexpressing mouse/humanchimeric APP with
the Swedish mutationand human presenilin-1 with deletion of exon 9. The coronalbrain sections are 12μm in thickness. Nuclei (blue) and
Aβ (red) were stained with Hoechst 33258 and antihuman Aβ antibody, respectively. (a) low-magniﬁcation view; (b) high-magniﬁcation
view. Bar = 20μmi n( a ) ;5μm in (b). (Reproduced from [85] with permission).
the repair of damaged neural tissues in vivo [101]. They
established a GD3-synthase gene knockout mouse model
in which all b-series gangliosides were deleted. However,
animals showed no morphological changes in the brains and
apparent abnormal behavior. Moreover, no diﬀerences in
Fas-mediated apoptotic reaction in lymphocytes compared
with the wild type were found. The mutant mice, however,
exhibited reduced regeneration of axotomized hypoglossal
nerves compared with the wild type, suggesting that b-series
gangliosides are more important in the repair of damaged
nerves rather than in the diﬀerentiation of the nervous
system.
7.Neurogenesisand NeuralStemCellsin
ADBrain
The neurodegenerative process in AD is initially charac-
terized by synaptic damage accompanied by neuronal loss.
Neuronal loss leads to cerebral atrophy, which appears to be
hallmarks of cognitive impairment in AD [102]. In addition
tothealterations insynaptic plasticity andneuronal integrity
in mature neuronal circuitries, the neurodegenerative pro-
cess in AD has recently been shown to be accompanied by
a l t e r a t i o n si nn e u r o g e n e s i s[ 103, 104]. The hippocampus is
one of the regions in the adult brain where neurogenesis
occurs throughout life [5]. Many studies have shown that
a d u l tn e u r o g e n e s i si si n v o l v e di nl e a r n i n ga n dm e m o r y .T h i s
has led to the hypothesis that impairment in memory during
aging and neurodegenerative diseases such as AD involves
abnormal neurogenesis [105]. However, neurogenesis in AD
and in animal models is not fully studied yet [106]. In AD
brains, there is some controversy whether neurogenesis is
increased[107]ordecreased[107].Boekhoometal.reported
an apparent increase of neurogenesis markers in AD brains,
which may be related to glial and vasculature-associated
changes [107]. A number of mouse models of AD displayed
reduced neurogenesis [108–110] or enhanced neurogenesis
[97]. Several attributes of adult hippocampal neurogenesis
suggest that amyloid deposition may inﬂuence neurogenesis
[111]. Zhang et al. reported that reductions in dentate gyrus
neurogenesis in a murine model of amyloid deposition are
linked to the deposition of amyloid [112].
The adult mammalian brain contains neural stem cells
(NSCs), undiﬀerentiated neural cells characterized by their
high proliferative potential and the capacity for self-renewal
with retention of multipotency to diﬀerentiate into neurons
and glial cells, in the subgranular zones of dentate gyrusInternational Journal of Alzheimer’s Disease 7
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Figure 2: The content of Chol-1α antigens, GT1aα (a) and GQ1bα (b), in AD model mouse brains [85]. GT1aα and GQ1bα extracted from
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Figure 3: Eﬀects of low (a) and high (b) concentrations of GM1 and Aβ1–40 on NECs. Basic ﬁbroblast growth factor (bFGF; 0 or 5ng/mL)
was added as a mitogen of NECs. The number of NECs cultured in the presence of bFGF for 4 days was estimated by WST-8 assay with
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absorbance (Abs.) measured at the wavelength of 450nm (reference, 650nm) by this assay is highly correlated with the number of living
NECs [113]. (Reproduced from [114] with permission).
and the subventricular zone (SVZ) of the lateral ventricles
[5]. The possibility that abnormalities in NSCs contribute
to the pathogenesis of AD and the cognitive impairments in
humans has been suggested [109, 110]. Several papers have
describedthephenomenonofneurogenesisinhippocampus,
and itseems tobe enhanced in ADbrains. This phenomenon
could potentially occur also in the brain of animal models of
AD, which points to the possibility of developing strategies
for promoting neurogenesis for AD therapy by using NSCs.
A number of studies have indicated that Aβsc a nr e g u l a t e
the proliferation of NSCs and documented the bifunctional
roles of Aβs on the cells in a dose-dependent manner. The
low concentrations of Aβsh a v en e u r o g e n i ce ﬀects in some
studies [115–117] but cytotoxic eﬀects in other studies [109,
118, 119]. Solubleoligomers of Aβ1–40 and Aβ1–42, but not
Aβ40–1, a reversed amino acid sequence, induced neuronal
apoptosis [120]. the aggregated form of Aβ1–42 stimulated
neurogenesis [117, 121]. In this regard, Aβ1–40 (0.5μmol/L)
signiﬁcantly reduced proliferation of endothelial progenitor
cells by about 65% compared to control whereas Aβ40–1
(0.5μmol/L), did not aﬀect their proliferation [122]. Gong
et al. reported that small, soluble oligomers of Aβ block
the reversal long-term potentiation [123]. Controversially, a
low micromolar concentration (1μM) of oligomeric Aβ1–
42 increased the proliferation [124] and neurogenesis of
adult NSCs [117]. Small peptide, Aβ1–16, had no eﬀect
on neuronal proliferation of adult SVZ progenitors [119,
121] Several studies indicated that Aβ25–35 has toxic eﬀects
and may induce cell death or apoptosis [109, 110, 118,
125, 126]. In contrast, Li and Zuo reported inhibitory
eﬀects of aggregated form of Aβ25–35 (1mg/mL, 3μL) on
neurogenesis in the SVZ and dentate gyrus after injection
into the lateral ventricle of adult mouse [127]. This result
indicates that Aβ25–35 could impair neurogenesis in the
hippocampus of adult mouse brain.
In neuronal cultures prepared from rat hippocampi
(embryonic day 18 to 19), it was reported that 25μMo f
Aβ25–35 enhanced the metabolism of lipids such as phos-
pholipids(+52%)and gangliosides(+193%),butnotcholes-
terol [128]. In addition, exposure of rat cultured cortical8 International Journal of Alzheimer’s Disease
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neurons to Aβ25–35 induced a substantial increase of the
intracellular GD3 levels [129]. These reports suggest that
Aβ can modulate ganglioside metabolism in NSCs. It has
been reported that in NSCs, GSLs, including gangliosides,
are involved in cellular proliferation via modulation of the
Ras-mitogen-activated protein kinase pathway [114]. These
ﬁndings prompt us to propose that a combination of Aβ
and GM1 induces NSC proliferation. Recently, we evaluated
the eﬀects of GM1 and Aβ1–40 on mouse neuroepithelial
cells (NECs) that are known to be abundant in NSCs [130].
In NECs cultured in the presence of lower concentrations
of GM1 (1, 5 or 10μM) and/or Aβ1–40 (1 or 5μM), there
w a sn od r a s t i cc h a n g eo ft h ec e l ln u m b e r( Figure 3(a)).
However, in NECs cultured in the presence of both 40μM
of GM1 and 10μMo fA β1–40, a signiﬁcant reduction of
the cell number was detected (Figure 3(b)). These exoge-
nouslyaddedGM1andAβ1–40wereeﬃcientlyincorporated
into NECs (Figure 4). In NECs simultaneously treated
with GM1 and Aβ1–40, the Ras-mitogen-activated protein
kinase pathway important for proliferation was intact, but
caspase-3, an executioner for cell death, was activated. Most
N E C st r e a t e dw i t hG M 1a n dA β1–40 were positive for
terminal deoxynucleotidyl transferase-mediated dUTP nick-
end labeling, an indicator of cell death accompanied with
DNA fragmentation. These results indicate that Aβ1–40 and
GM1cooperativelyexertacytotoxiceﬀectonNECs,likelyvia
incorporation into NEC membranes where the formation of
a complex results in activation of cell death signaling.
Several reports have indicated that gangliosides added
exogenously in the culture medium have bifunctional eﬀects
on neural cell proliferation. Gangliosides added exogenously
at the concentration of micromolar levels were found to
inhibit neuritogenesis in human neuroblastoma cells, SH-
SY5Y [131]. However, under physiological conditions, GM1
enhanced nerve growth factor-induced neurite outgrowth,
neurite complexity, and neuronal cell survival following
nerve growth factor withdrawal using fetal-chick dorsal root
ganglia [132] and induced neurite sprouting in culture neu-
rons [133]. GQ1b induced phosphorylation of cell surface
proteins in a human neuroblastoma cell line, GOTO [134].
The eﬀects of gangliosides exogenously added remained
obscure and seem to vary from one cell line to another
and the culture conditions [7]. Therefore, further studies are
neededtoclarifytherelationshipbetweenGM1andAβinthe
proliferationofNECs.Inaddition,evaluationoftheeﬀectsof
exogenous GM1 on neurogenesis and pathogenesis of AD in
pathological conditions, for instance, using AD model mice
[135] will be an interesting and fruitful subject for futureInternational Journal of Alzheimer’s Disease 9
studies. Many studies showed that NSCs improved neuronal
survival in cultured postmortem brain tissue from aged and
AD patients [136]. Further studies to understand the roles
of GM1 and Aβs on NSCs in AD should contribute to the
development of new regenerative therapies of this disease.
8.Conclusions
There is increasing consensus that AD is characterized in the
brainbyaggregated amyloid depositsin SPs.The aggregation
of Aβ plays a pivotal role in the pathogenesis of AD that
is intimately linked to neuronal toxicity and inhibition of
hippocampal long-term potentiation. At present, there is
no cure for AD, although some drugs inhibiting acetyl-
cholinesterase haveprovedtobecurrenttreatment topalliate
both cognitive and behavioral symptoms within a limited
time. Researchers are looking for new treatments to alter
t h ec o u r s eo ft h ed i s e a s ea n di m p r o v et h eq u a l i t yo fl i f e
for patients with AD and related dementia. Aβ is currently
clariﬁed to interact with gangliosides with high aﬃnities. In
fact, a complex of GM1 (and possibly other gangliosides)
with Aβ,t e r m e dG A β, was found to accumulate in the
AD brains. An antibody against GAβ was proved to block
amyloid ﬁbril formation, suggesting that it can contribute
to the development of a novel therapeutic strategy to AD.
In this regard, drugs such as nordihydroguaiaretic acid,
rifampicin, and tannic acid are found to be potent inhibitors
of the binding of GM1 and Aβ, resulting in inhibition
of membrane-mediated formation of Aβ ﬁbrils in vitro.
T h e s ed r u g sa r eu s e f u la g e n t sf o rA Dt h e r a p y[ 137]. On
the other hand, in AD model mice lacking GD3-synthase,
Aβ plaques and associated neuropathology are almost com-
pletelyeliminated,resultingincognitiveimprovement.GD3-
synthase and its downstream metabolic products, the b-
series gangliosides, can be a novel therapeutic target for
repressing neurodegeneration and cognitive deﬁcits that
aﬄict AD patients. Another promising therapeutic strategy
for AD is cell replacement therapy using NSCs. Although
neurogenesis in AD brains is still controversial, transplan-
tation of NSCs into the damaged brain regions may be
beneﬁcial for neural regeneration in AD. For therapeutic use
of NSCsin AD, however, it should be essential to fully clarify
the eﬀects of Aβs and gangliosides on NSC fate regulation.
Future therapies for treating AD will include agents that
modulate GSL metabolism, either as primary therapeuticsor
in combination with other drugs.
The nomenclatureforgangliosidesisbasedonthesystem
of Svennerholm [138].
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